X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ASTRAZENECA PHARMA VENUS REMEDIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x -8.9 144.2 - View Chart
P/BV x 0.1 21.9 0.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1431,285 11.1%   
Low Rs65634 10.3%   
Sales per share (Unadj.) Rs324.2189.6 171.0%  
Earnings per share (Unadj.) Rs6.4-0.2 -3,148.4%  
Cash flow per share (Unadj.) Rs40.63.8 1,055.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.068.6 533.2%  
Shares outstanding (eoy) m12.3425.00 49.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.1 6.3%   
Avg P/E ratio x16.2-4,712.7 -0.3%  
P/CF ratio (eoy) x2.6249.6 1.0%  
Price / Book Value ratio x0.314.0 2.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,28223,988 5.3%   
No. of employees `0000.91.6 57.9%   
Total wages/salary Rs m2511,605 15.6%   
Avg. sales/employee Rs Th4,430.13,040.2 145.7%   
Avg. wages/employee Rs Th278.01,029.2 27.0%   
Avg. net profit/employee Rs Th87.6-3.3 -2,683.0%   
INCOME DATA
Net Sales Rs m4,0004,740 84.4%  
Other income Rs m2392 24.6%   
Total revenues Rs m4,0234,832 83.3%   
Gross profit Rs m785-130 -604.5%  
Depreciation Rs m422101 416.6%   
Interest Rs m3440-   
Profit before tax Rs m42-139 -30.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m-375 -726.9%   
Profit after tax Rs m79-5 -1,554.0%  
Gross profit margin %19.6-2.7 -716.3%  
Effective tax rate %-87.9-3.7 2,398.3%   
Net profit margin %2.0-0.1 -1,841.2%  
BALANCE SHEET DATA
Current assets Rs m2,6062,726 95.6%   
Current liabilities Rs m1,9802,435 81.3%   
Net working cap to sales %15.66.1 254.5%  
Current ratio x1.31.1 117.5%  
Inventory Days Days12874 174.0%  
Debtors Days Days4341 105.9%  
Net fixed assets Rs m5,3531,035 517.1%   
Share capital Rs m12350 246.8%   
"Free" reserves Rs m4,393942 466.1%   
Net worth Rs m4,5161,716 263.2%   
Long term debt Rs m1,6180-   
Total assets Rs m8,2914,156 199.5%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.1 42.3%   
Return on assets %5.1-0.1 -4,163.7%  
Return on equity %1.8-0.3 -590.5%  
Return on capital %6.30-  
Exports to sales %05.7 0.0%   
Imports to sales %18.46.5 284.8%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs m736306 240.4%   
Fx inflow Rs m0375 0.0%   
Fx outflow Rs m736470 156.6%   
Net fx Rs m-736-96 770.6%   
CASH FLOW
From Operations Rs m997-8 -12,311.1%  
From Investments Rs m-461-146 316.6%  
From Financial Activity Rs m-571862 -66.2%  
Net Cashflow Rs m-35709 -5.0%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 60.0%  
FIIs % 0.6 15.7 3.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 9.1 729.7%  
Shareholders   20,121 12,856 156.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

OPEC Meeting; Upcoming IPOs; IDBI Bank, Emami among Top Stocks in Action Today(Pre-Open)

Indian share markets edged up on Friday with Nifty 50 closing above 10,800-levels, even as broader global markets remained weak.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 25, 2018 09:31 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - NOVARTIS COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS